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Abstract
Background:  Portal vein thrombosis (PVT) is increasingly frequently being diagnosed, but
systematic descriptions of the natural history and clinical handling of the condition are sparse. The
aim of this retrospective study was to describe risk factors, clinical presentation, complications and
treatment of portal vein thrombosis in a single-centre.
Methods: Sixty-seven patients were identified in the electronic records from 1992 to 2005. All
data were obtained from the patient records.
Results: One or more risk factors (e.g. prothrombotic disorder or abdominal inflammation) were
present in 87%. Symptoms were abdominalia, splenomegaly, fever, ascites, haematemesis, and
weight loss. Abdominalia and fever occurred more frequently in patients with acute PVT. Frequent
complications were splenomegaly, oesophageal- and gastric varices with or without bleeding, portal
hypertensive gastropathy and ascites. Varices and bleeding were more frequent in patients with
chronic PVT. Patients who received anticoagulant therapy more frequently achieved partial/
complete recanalization. Patients with varices who were treated endoscopically in combination
with β-blockade had regression of the varices. The overall mortality was 13% in one year, and was
dependent on underlying causes.
Conclusion: Most patients had a combination of local and systemic risk factors for PVT. We
observed that partial/complete recanalization was more frequent in patients treated with
anticoagulation therapy, and that regression of varices was more pronounced in patients who
where treated with active endoscopy combined with pharmacological treatment.
Background
Over the last years, portal vein thrombosis (PVT) is
increasingly frequently being diagnosed by wide use of
ultrasound-Doppler equipment. Recently, the lifetime
risk of getting PVT in the general population is reported to
be 1% [1]. The condition, thus, attracts more focus. The
conception of the severity of the problem among treating
physicians varies between desolate and unimportant. The
recommended therapeutic approach varies between one
of expectancy and active intervention aimed at supposed
risk factors and complications. Accordingly, there is a
need for a basis for clinical decisions.
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Risk factors and complications to PVT have become better
defined although most of the information derives from
patients with cirrhosis [2,3]. Still, the rational manage-
ment of PVT is still not adequately understood, and there
have been no controlled studies. Based on some case-
series, anticoagulation may be associated with recanaliza-
tion of both acute [4,5] and chronic thrombosis [6]. Band
ligation remains central in treating acute variceal bleed-
ing. Secondary prophylaxis of rebleeding with ligation is
effective; however, there are insufficient data on β-block-
ade alone or in combination with endoscopy [7-9].
PVT seems most often to develop in the presence of both
systemic and local risk factors [10,11], but the relative
importance of these factors for the course and treatment
strategy of the condition remains unclear.
Thus, there are several unresolved issues regarding PVT
that due to the rarity of the condition cannot be clarified
by large trials.
Therefore, the aim of this case-series was to describe risk
factors, clinical presentation, complications, treatment
and outcome in patients with PVT in a tertiary university
hospital.
Methods
Sixty-seven patients were identified in the computerised
hospital administrative registration system by the ICD10
classification code I81.9. All cases from January 1992 to
December 2005 of extrahepatic portal vein thrombosis or
intrahepatic portal vein thrombosis were included. All
registered diagnoses were based on either ultrasound with
Doppler, CT-angiography or MRI. Diagnostic inclusion
criteria were partial or complete thrombosis with the
extension of the thrombus defined. Follow-up elapsed
from the time of admission, and lasted to either death or
December 31st 2005.
The following data were extracted from the clinical
records: sex, age, risk factors (prothrombotic tendency,
cirrhosis, cancer, abdominal inflammation, infection, sur-
gical abdominal intervention, none), clinical presenta-
tion; abdominalia (= abdominal pain, loss of appetite,
nausea, vomiting or diarrhoea), splenomegaly, fever,
ascites (tense/soft, diagnosed by clinical evaluation or
ultrasound), haemorrhage (= haematemesis, melaena or
rectal bleeding), presentation of PVT (acute < 60 days or
chronic > 60 days [4]), complications (oesophageal- and
gastric varices, variceal haemorrhage, portal hypertensive
gastropathy, ascites), extension of the thrombus (intra-
and/or extrahepatic, superior mesenteric vein or splenic
vein), information on coagulation disorders, imaging
methods (Doppler ultrasound, CT angiography, MRI, and
endoscopy), treatment (anticoagulation, thrombolysis,
sclerotherapy, banding, β-blockade, long-acting nitrates
and transjugular intrahepatic portosystemic shunting
(TIPS)), the course of varices, recanalization and finally
the cause of death.
Diagnosis of portal hypertensive gastropathy and grading
of oesophageal- and gastric varices was made by means of
endoscopy. Thrombophilia investigation was performed
by using citrated plasma and heparin-flouride containing
plasma collected by venipuncture and kept at -80°C until
analysis. The protocol for sample collection and process-
ing, as well as data interpretation, has been reported in
previous publications [12-14].
Thrombophilia testing included collection for anti-
thrombin (AT), homocystein, protein C, free protein S,
factor V (FV) Leiden, prothrombin G20210A, Von Wille-
brand-factor, activated protein C resistance, β-2 glycopro-
tein-1 (APA), phospholipid antibody, and lupus
anticoagulant (LA). The spontaneous fibrinolytic capacity
was determined by a routine fibrin plate technique.
Due to the severity of cancer and cirrhosis, we stratified
the patients in two groups: 1. Patients without cancer or
cirrhosis and 2. Patients with cancer or cirrhosis. Data
from the two groups were analysed separately. Results for
the group of patients without cancer and cirrhosis (n = 48)
will be presented and compared with results for the group
of patients with cancer or cirrhosis (n = 19).
All analyses were done using Stata version 9.2. Signifi-
cance was calculated with Student's t-test or Chi squared
test. P < 0.05 was considered statistically significant in a
two-sided test.
Ethical consideration
The Central Denmark Region Committee on Biomedical
Research Ethics confirmed that no approval was required
for this study.
Results
Basic data
For patients without cancer and cirrhosis, mean age at
time of admission was 44 ± 17 SD (range 15–74). The
group included 23 women and 25 men. Seventeen had
acute PVT and 31 chronic PVT. There was no difference in
age between genders, but higher age in patients with acute
(51 ± 16) compared to chronic (40 ± 16) PVT at time of
diagnosis. Mean time elapsed from time of admission was
39 ± 41 months (range 0–158).
For patients with cancer and cirrhosis, mean age at time of
admission was 57 ± 12 SD (range 34–78). Six were
women and 13 men. Ten had acute PVT and 9 chronic
PVT. There was no difference in age between genders, orBMC Gastroenterology 2007, 7:34 http://www.biomedcentral.com/1471-230X/7/34
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between acute and chronic PVT at time of diagnosis. Mean
time elapsed from time of admission was 26 ± 27 months
(range 0–92).
Risk factors (Table 1)
Risk factors were established in 58 cases (87%). Twenty-
nine cases (43%) had two risk factors, and 14 (21%) had
three risk factors.
When including all risk factors, 43 cases (64%) had a local
risk factor, and 28 cases (42%) had a systemic risk factor.
Analyses of patients without cancer or cirrhosis showed a
difference of risk factors: 27 cases (56%) had a local risk
factor, and 24 cases (50%) a systemic risk factor.
Imaging methods
In 51 (76%) patients, diagnosis was established by means
of Doppler ultrasound. Of 12 patients with a negative
ultrasound, 11 were diagnosed by CT angiography and
one by MRI-scanning. In four patients, the diagnosis was
initially established with CT or MRI. In all patients diag-
nosed by means of Doppler ultrasound, CT angiography
was later performed. MRI-scanning was only performed in
five of the patients with a positive Doppler ultrasound,
and supported the diagnosis in all five cases. Sensitivity
was calculated to be 81% (51/63) for Doppler ultrasound
and 94% (51/54) for CT. Anatomical location was in 65
cases (97%) extrahepatic, and in two cases (3%) intrahe-
patic. In addition, patients with extrahepatic PVT also had
intrahepatic thrombosis (54%) and/or in the splenic vein
(42%), and/or in superior mesenteric vein (31%), and
one patient also had thrombosis of the inferior mesenteric
vein.
Clinical manifestation (Table 2)
In the analysis of patients without cancer or cirrhosis,
71% presented with abdominalia, 75% splenomegaly,
31% fever, 38% ascites, 19% haemorrhage and 33%
weight loss. Abdominalia and fever were more frequent
symptoms in the acute disease.
In the analysis of patients with cancer or cirrhosis, 63%
had abdominalia, 63% splenomegaly, 37% fever, 32%
ascites, 58% haemorrhage and 16% weight loss.
Patients with ascites had light to moderate ascites and
28% were treated with paracentesis.
Complications (Table 3)
Fifty-nine patients had one or more complications.
Among patients without cancer or cirrhosis, 72% had
oesophageal varices, 42% gastric varices, 44% portal
hypertensive gastropathy, 29% variceal haemorrhage, and
42% ascites. Of 36 patients with oesophageal varices, 20
Table 1: Risk factors of portal vein thrombosis in all patients (n = 67)
Primary risk factor All risk factors
Prothrombotic disorder n = 19 (28%) Prothrombotic disorder n = 36 (54%)
Hyperhomocysteinemia (n = 13), antiphospholipid syndrome (n = 9), hormone replacement therapy 
(n = 2), Factor V Leiden mutation (n = 3), Protein C deficiency (n = 2), Polycythaemia vera (n = 2), 
myeloproliferative syndrome (n = 1), Protein S deficiency (n = 1), antitrombin III deficiency (n = 1), 
disseminated coagulation (n = 1), essential thrombocytosis (n = 1)
Abdominal inflammation n = 13 (19%) Abdominal inflammation n = 23 (34%)
Chronic pancreatitis (n = 11), Cholangitis (n = 5), acute pancreatitis (n = 2), liver abscesses (n = 2), 
umbilical vein catheterization (n = 1), cholecystolithiasis (n = 1), polycystic liver disease (n = 1)
Cirrhosis n = 9 (13%) Cirrhosis n = 12 (18%)
Cancer n = 7 (11%) Cancer n = 9 (13%)
Neuro-endocrine Tumor (n = 4)*, hepatocellular carcinoma (n = 2), pancreatic cancer (n = 1), 
unknown primary tumour (n = 1), angiomyxoma (n = 1)
Abdominal intervention n = 5 (8%) Abdominal intervention n = 8 (12%)
Splenectomy (n = 3), cholecystectomy (n = 2), Billroth II (n = 1), radiofrequency ablation (n = 1), 
gastropancreaticcystotomy (n = 1)
Abdominal infection n = 5 (8%) Abdominal infection n = 9 (13%)
Bacteraemia (n = 4), portal vein phlebitis (n = 2), intestinal tuberculosis (n = 1), sepsis (n = 1), 
tuberculosis in psoas abscess (n = 1)
Idiopathic n = 9 (13%) Idiopathic n = 9 (13%)
* A relative large proportion reflecting the centre's specialist function for this disease. Patients can have more than one risk factor.BMC Gastroenterology 2007, 7:34 http://www.biomedcentral.com/1471-230X/7/34
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(56%) also had gastric varices. Oesophageal varices and
bleeding were more frequent in patients with chronic PVT.
Among patients with cancer or cirrhosis, 63% had
oesophageal varices, 42% gastric varices, 37% portal
hypertensive gastropathy, 43% variceal bleeding, and
42% ascites. Of 12 patients with oesophageal varices, six
also had gastric varices.
Treatment
Twenty-seven (56%) of the patients without cancer or cir-
rhosis received anticoagulation therapy (vitamin K-antag-
onist, low molecular weight heparin or heparin),
compared with only 32% of the patients with cancer or
cirrhosis. One patient with extensive thrombosis received
recombinant tissue plasminogen activator, and in three
patients, transjugular (or transhepatic) intrahepatic porto-
systemic shunt was established.
Forty-five percent (10 acute and five chronic) of the
patients without cancer or cirrhosis who received antico-
agulation therapy (16 acute and 11 chronic) improved
their portal flow with partial or complete recanalization
during follow up. All four patients with cancer or cirrhosis
and acute PVT (67%) who received anticoagulation ther-
apy had partial or complete recanalization. Among such
patients who did not receive anticoagulation therapy (n =
34), only 15% improved their portal flow and had any
degree of spontaneous resolution of the thrombosis.
Of patients with oesophageal varices (n = 48), 60% of the
patients without, and (n = 12) 75% of patients with can-
cer of cirrhosis were treated endoscopically with band
ligation (VBL) and/or sclerotherapy, in 24% as primary
prophylaxis. Forty-two percent of patients without and
17% of patients with cancer or cirrhosis were treated with
β-blockers as primary prophylaxis. Of patients with one or
more variceal bleeding episodes (n = 24), 92% of patients
without and 80% with cancer or cirrhosis were treated
with VBL or sclerotherapy, and 88% with and 90% with-
out cancer or cirrhosis with β-blockers (24% of these also
with long-acting nitrates) as secondary prophylaxis.
Table 3: Complications in patients with cancer or cirrhosis, and patients without cancer and cirrhosis
Analysis Patients with cancer or cirrhosis N = 19 Patients without cancer and cirrhosis N = 48
Presentation Presentation
Acute Chronic N (% of total) Acute Chronic N (% of total)
Portal hypertensive gastropathy 4 (40%) 3 (33%) 7 (37%) 5 (29%) 16 (52%) 21 (44%)
Gastric varices 4 (40%) 4 (44%) 8 (42%) 4 (24%) 16 (52%) 20 (42%)
Oesophageal varices, small 4 (40%) 6 (67%) 10 (53%) 7 (41%) 18 (58%) 25 (52%)
Oesophageal varices, large 1 (10%) 1 (11%) 2 (11%) 1 (6%) 10 (32%) 1 (23%)
Haemorrhages (1–2) 2 (20%) 4 (44%) 6 (32%) 0 10 (32%) 10 (21%)
Haemorrhages (repeated) 3 (30%) 1 (11%) 4 (21%) 0 4 (13%) 4 (8%)
Ascites 4 (40%) 4 (44%) 8 (42%) 8 (47%) 12 (39%) 20 (42%)
Total 10 (53%) 9 (47%) 19 (100%) 17 (35%) 31 (65%) 51 (100%)
*Data are presented as N of total number and % within acute/chronic presentation.
Table 2: Clinical presentation in patients with cancer or cirrhosis, and patients without cancer and cirrhosis
Analysis Patients with cancer or cirrhosis N = 19 Patients without cancer and cirrhosis N = 48
Presentation Presentation
Acute Chronic N (% of total) Acute Chronic N (% of total)
Abdominalia 7 (70%) 5 (56%) 46 (63%) 16 (94%) 18 (58%) 34 (71%)
Splenomegaly 7 (70%) 5 (56%) 12 (63%) 10 (59%) 26 (84%) 36 (75%)
Fever 5 (50%) 2 (22%) 7 (37%) 10 (59%) 5 (16%) 15 (31%)
Haemorrhage 6 (22%) 5 (35%) 11 (58%) 0 9 (29%) 9 (19%)
Ascites 4 (40%) 2 (22%) 6 (32%) 8 (47%) 10 (38%) 18 (38%)
Weight loss 1 (10%) 2 (22%) 3 (16%) 9 (53%) 7 (23%) 16 (33%)
Total 10 (53%) 9 (47%) 19 (100%) 17 (35%) 31 (65%) 48 (100%)
*Data are presented as N of total number and % within the acute/chronic presentation.BMC Gastroenterology 2007, 7:34 http://www.biomedcentral.com/1471-230X/7/34
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Of the patients with varices who were treated endoscopi-
cally, 90% of patients with and 100% without cancer or
cirrhosis also received medical treatment with β-blockers,
and of these, respectively 58% and 63% showed regres-
sion of varices during follow-up. Seven patients with
varices received no treatment, and their varices remained
unchanged or progressed.
Mortality
Of patients without cancer or cirrhosis, eight (17%) died
during follow up. The causes of death were variceal bleed-
ing (n = 1), profuse intrahepatic bleeding after tromboly-
sis (n = 1), infection (n = 1), pulmonary embolism (n =
1), acute myocardial infarction (n = 1), florid pseu-
domembraneous colitis (n = 1) and unknown (n = 2). Of
patients with cancer and cirrhosis, six (32%) patients died
during follow-up; causes of death were renal insufficiency
(n = 2), liver failure (n = 2), cancer (1) and unknown (1).
Risk factors of PVT were cirrhosis (n = 4), prothrombotic
disorder (n = 4), cancer (n = 2), unknown (n = 2), splenec-
tomy (n = 1) and chronic pancreatitis (n = 1). Within the
first year after diagnosis of PVT (and admission to our
hospital), four (8%) of the patients without cancer or cir-
rhosis died, and five (26%) of the patients with cancer or
cirrhosis died.
Discussion
Retrospectively, we report risk factors and prognostic data
on 67 patients with PVT referred to a single centre univer-
sity hospital in Denmark between 1992 and 2005.
The main limitation of this study is lack of generalizability
due to its retrospective nature; however, large-scale ran-
domised trials of such rare conditions can not be con-
ducted, and, to our knowledge, this is one of the larger
retrospective studies of PVT. In accordance with previ-
ously published studies, we found that PVT developed
because of several risk factors [9,15,16]. In the restricted
analysis, we found a combination of local (56%) and sys-
temic risk factors (50%). Denninger et al. [17] reported a
higher incidence of systemic factors (72%).
Only 11% of our PVT patients with cirrhosis and none of
those with cancer were screened for coagulation disorders.
However, it is important systematically to screen patients
with a life expectancy of more than 3–6 months and
where anticoagulation therapy is considered relevant, and
particularly cirrhosis patients, since 70% of these report-
edly have a genetic thrombogenic predisposition [18].
The typical presentation of acute PVT was abdominalia,
splenomegaly, fever and ascites, while the presentation of
chronic PVT was abdominalia and splenomegaly together
with gastrointestinal haemorrhages and ascites. We found
a higher frequency of abdominalia and fever in patients
with acute PVT than in those with chronic PVT. Other
studies report the same presentation, though ascites is
described only in few cases of acute PVT [9,15]. The high
presenting occurrence of ascites among our patients may
be due to the fact that we registered ascites both when
detected by physical examination and by ultra sound, so
that cases of slight ascites were included. The ascites was
in no case tense (although some were treated with para-
centesis to speed up recovery). Ascites in such patients is
most likely caused by intestinal venous congestion,
whereas the mechanisms leading to massive fluid reten-
tion are not activated as at sinusoidal portal hypertension.
Frequent complications during follow-up were oesopha-
geal- and gastric varices, portal hypertensive gastropathy,
bleeding from varices and ascites. A larger part of patients
with chronic PVT developed oesophageal varices in com-
parison with patients with acute PVT. Thus, the develop-
ment of varices is a time dependent phenomenon, and it
is advisable to screen all PVT patients endoscopically.
Twenty-nine percent of patients without cancer or cirrho-
sis experienced variceal bleeding (in patients with cancer
or cirrhosis 53%), in only one patient fatal, in accordance
with other reports [6,19].
Spontaneous resolution of the thrombosis did happen in
some cases, but the frequency of partial/complete recanal-
ization seemed to be higher in patients treated with anti-
coagulation therapy. The effect was seen in patients with
both acute and chronic PVT. The aim of anticoagulation
therapy is both to prevent further thrombosis, and poten-
tially lead to recanalization, thereby preventing the devel-
opment of portal hypertension and its complications. It
has been suggested that interventional recanalization
should be performed whenever the result of anticoagula-
tion is unsatisfactory, and furthermore, that portal stents
should be implanted in patients with cirrhosis [20]. One
study showed no increased rate of bleeding episodes in
patients with established PVT who received anticoagulant
therapy [6]. However, to our knowledge, there is yet no
consensus on the indication for anticoagulant therapy [9].
For primary prophylaxis, β-blockade is standard for cir-
rhotic portal hypertension, but the effect is not docu-
mented in PVT, and VBL may be preferable. In the acute
management of variceal bleeding, vasoactive substances,
antibiotics, and VBL remain central. For secondary proph-
ylaxis of re-bleeding we used combined VBL and β-block-
ade ± long-acting nitrates [7,8,21,22] although evidence
to support β-blockers is sparse [9]. In any case, our
patients showed regression of their varices when given
this combination preventive treatment.
In accordance with others, we found that the outcome of
PVT in general is good, and that mortality primarily wasPublish with BioMed Central    and   every 
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associated to underlying cause and less to the conse-
quences of portal hypertension [6,20,23,24]. Mortality in
one year was highest in patients with cancer or cirrhosis,
26% compared with only 8% in patients without these
diseases.
Conclusion
In conclusion, most patients had a combination of local
and systemic risk factors for PVT. We observed that par-
tial/complete recanalization was more frequent in
patients treated with anticoagulation therapy, and that
regression of varices was more pronounced in patients
who were treated with active endoscopy combined with
pharmacological treatment.
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